News Summary

Paradromics, an Austin-based brain implant developer, has received FDA approval to conduct early-stage human trials for its Connexus brain implant. This trial aims to restore speech in individuals with severe motor impairments by using brain-computer interfaces (BCIs) to capture and translate brain signals into synthesized speech and text communication. The initial phase of the trial will involve two participants, with plans to expand upon successful data collection. The technology does not read thoughts but decodes signals from the brain’s motor cortex to assist in speech communication. Paradromics’ implant is a metal disk with 421 microwire electrodes that records signals from individual neurons.